Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 247

Sort by

Sort Order Select

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Blood (2024) 144 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2024-201896

Published: 2024

Journal Articles

Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study

Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Tian Tian, Andy Szeto, Roman Korolkiewicz, Constantine S. Tam, Wojciech Jurczak

Blood (2024) 144 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2024-194864

Published: 2024

Journal Articles

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2024) 144 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2024-210594

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration

Imran A. Nizamuddin, Narendranath Epperla, Mary-Kate Malacek, Brad S. Kahl, Fei Wan, Anne Fischer, Chaz Moreno, Emily R. King, Anna Krivenko, Nancy L. Bartlett, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 985.

https://doi.org/10.1182/blood-2024-204521

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2024-201078

Published: 2024

Journal Articles

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Alvaro J Alencar, Susan M. Geyer, Electra D Paskett, Levi D. Pederson, Travis Dockter, Nilanjan Ghosh, Kehinde Adekola, Joseph M Unger, Opeyemi Jegede, Jonathan W. Friedberg, Brad S. Kahl, Shira N. Dinner, Nancy L. Bartlett, Kristie A. Blum, John P. Leonard

Blood (2024) 144 (Supplement 1): 110.

https://doi.org/10.1182/blood-2024-209365

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Prognostic Significance of Clinical Characteristics and Baseline PET-CT Metabolic Parameters in Patients with Marginal Zone Lymphoma

Imran A. Nizamuddin, Adeel Haq, Fei Wan, Marcus P. Watkins, Lauren Kelly Shea, Nancy L. Bartlett, Brad S. Kahl, Joyce Mhlanga, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 6334.

https://doi.org/10.1182/blood-2024-204458

Published: 2024

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Anne W Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J Alencar, Shira N. Dinner, Eric D. Hsi, Meng Welliver, Daniel Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 1661.3.

https://doi.org/10.1182/blood-2024-207372

Published: 2024

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

David A Russler-Germain, Fei Wan, Emily R. King, Chaz Moreno, Michelle Becker-Hapak, Patrick Pence, Joseph Rueve, Sushanth A Pureti, Dilan A. Patel, Brad S. Kahl, Neha Mehta-Shah, Todd A Fehniger, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 4414.

https://doi.org/10.1182/blood-2024-202085

Published: 2024

Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Blood (2024) 144 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2024-198687

Published: 2024

Journal Articles

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Mazie Tsang, Urshila Durani, Jonathan R Day, Melissa C. Larson, Matthew Holets, Kathleen J Yost, Jonathon B. Cohen, Jonathan W. Friedberg, Izidore S. Lossos, Peter Martin, Brad S. Kahl, Thomas M. Habermann, Loretta Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Carla Casulo, Matthew J. Maurer

Blood (2024) 144 (Supplement 1): 7598.

https://doi.org/10.1182/blood-2024-210968

Published: 2024

NARROW

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Prognostic Significance of Clinical Characteristics and Baseline PET-CT Metabolic Parameters in Patients with Marginal Zone Lymphoma

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only